Emily Mason‐Osann

<i>In Vitro</i> and <i>In Vivo</i> Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

Kevin Hollevoet, Emily Mason‐Osann, Xiufen Liu et al. · Molecular Cancer Therapeutics · 2014 · 100 citations · Full text

Medicine, Oncology, Pharmacology +9

SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance

Stephanie Panier, Marija Marić, Graeme Hewitt et al. · Molecular Cell · 2019 · 90 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +17

Identification of a novel gene fusion in ALT positive osteosarcoma

Emily Mason‐Osann, Anqi Dai, Jess Floro et al. · Oncotarget · 2018 · 47 citations · Full text

Medicine, Molecular Biology, Oncology +17

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results

Emily Mason‐Osann, Kevin Hollevoet, Gerhard Niederfellner et al. · Scientific Reports · 2015 · 24 citations · Full text

Medicine, Oncology, Pharmacology +11

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line

Kevin Hollevoet, Emily Mason‐Osann, Fabian Müller et al. · PLoS ONE · 2015 · 14 citations · Full text

Life Sciences, Immunology, Molecular Biology +14